Introduction
Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the gastrointestinal tract and account for approximately 25% of soft tissue sarcomas. They are thought to arise from the intestinal cells of Cajal (1) or from a common progenitor cell (2). Most GISTs (80%) have activating mutations in the KIT tyrosine kinase receptor gene, but 8% have platelet-derived growth factor receptor α (PDGFRA) mutations (3,4) and a few of the remainder have BRAF mutations (5). In addition to these mutations, the most frequently reported genetic changes are 14q, 22q
and 1p losses (6).
Clinical management of GISTs consists mainly of surgical resection and adjuvant targeted therapy with imatinib mesylate (Gleevec, Novartis Pharma AG), which targets mutationally activated KIT or PDGFRA signaling (7). Around 20-40% of patients relapse, with distant liver metastasis being the most common manifestation of recurrence. It is mainly patients with these aggressive GISTs who benefit from imatinib therapy. Precise evaluation of metastatic risk is therefore highly desirable.
Many pathological criteria based on tumor site, tumor size, cell type, degree of necrosis and mitotic rate have been proposed for predicting the outcome of patients with GISTs. A consensus grading scheme based on tumor size and mitotic count was Author Manuscript Published OnlineFirst on December 13, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1610 metastatic risk is poorly defined. Hence, there is a need to better understand GIST biology in order to identify biomarkers causally linked to poor outcome.
To address this need, multiple DNA copy number and gene expression studies have been performed but, for a variety of reasons including small sample size and availability of clinical data, the results were generally inconclusive. It has been shown that the number and complexity of genomic rearrangements increase with tumor stage but no threshold has been defined (6, (10) (11) (12) (13) (14) (15) (16) . At the expression level, Yamaguchi and colleagues reported a gene-expression signature based on 32 GISTs that predicts outcome, but only in gastric GISTs (17).
We recently established a 67 gene prognostic signature related to chromosome integrity, mitotic control and genome complexity in sarcomas (CINSARC for Complexity INdex in SARComa) (18) . To assess the effectiveness of this signature in GISTs we have used it to score 67 fully annotated primary untreated GISTs. To identify the underlying mechanisms leading to high CINSARC scores we have performed genomewide DNA copy number and gene expression analyses of these tumors.
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Quantitative genomic and RT-PCR
The copy number status of p14, p15 and p16 was determined as previously described (19) . A normal status was assigned to a ratio ≥0.8 and ≤1.2. A ratio >0.1 and <0.8 was scored as a hemizygous deletion. When ratio was below 0.1, the deletion was scored as homozygous.
Reverse transcription and quantitative PCR for p14, p16, AURKA and RB1 were performed as previously described (19) . A reference CT (threshold cycle) for each sample was defined as the average measured CT of the three reference genes, GAPDH, ACTB and RPLP0. Relative mRNA level in a sample was defined as: ΔCT = CT (gene of interest) -CT (mean of the three reference genes).
Immunohistochemistry
Immunohistochemistry experiment was realized on tissue microarrays (TMA) containing 15 cases from the present series and performed as previously described (20). Antigen retrieval was achieved using the Dako Target Retrieval Solution, pH9 for 20 min at 98°C. Slides were incubated for 1h with the AURKA antibody used at a dilution of 1:50 (Novocastra, NCL-L-AK2, clone JLM28). Each case was spotted in triplicate on the TMA and we used the average value of the three spots.
Statistical analysis.
The CINSARC centroids are mean-centered reference profiles for the CINSARC signature genes in the 310 metastatic and non-metastatic sarcomas from our previous study (18). Each GIST was allocated to the prognostic class with the highest Spearman correlation to the reference centroids.
Author Manuscript Published OnlineFirst on December 13, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1610 date of initial diagnosis to the date of first metastasis, relapse, last follow-up or death for patients without diagnosis of metastasis. Survival curves were compared with the log rank test. All survival analyses were performed using R software version 2.11.11 and the "survival" package. Hazard ratios and multivariate analysis were performed with the Cox proportional hazard model or Cox regression with the Firth's correction (R software, "coxph" package) depending on occurrence or not of events in the reference group.
Results

Is CINSARC a significant prognostic factor for GISTs?
To test whether the CINSARC signature has prognostic value in GISTs, we performed gene expression profiling on a series of 60/67 (89.5%) GISTs with mRNA of sufficient quality (table 1) . We assigned these tumors to prognostic groups based on correlation with the published CINSARC centroids from our previous series of 310 No metastasis or other relapse event occurred in the good prognosis group.
Is it possible to derive a better signature specifically for GISTs?
The CINSARC signature is based on several different types of sarcoma. To test whether it is possible to derive a better signature that is specific for GISTs, we analyzed the GIST gene expression profiles to identify genes differentially expressed by the metastatic and non-metastatic tumors. Among the 297 differentially expressed genes (supplementary table 1), 70 (86 probe sets) were down-regulated and 227 (252 probe sets) were up-regulated in metastatic cases (FC > 3 and P < 0.001). Gene Ontology (GO) analysis identified no significantly enriched pathways for the 70 down-regulated genes. In contrast, Gene Ontology (GO) analysis revealed that 32 of the 40 (80%) pathways containing up-regulated GIST genes were also identified by GO analysis with the CINSARC genes (supplementary table 2). Indeed, 45 of the 227 up-regulated GIST genes belonged directly to the CINSARC signature. Moreover, GO analysis of the remaining 182 differentially regulated genes not included in CINSARC signature
Author Manuscript Published OnlineFirst on December 13, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1610 showed enrichment for the same pathways as for the CINSARC genes (supplementary , fig. 2b ).
Is there a genomic explanation for AURKA over-expression?
To test the hypothesis that AURKA amplification could account for the AURKA over-expression, we performed CGH to determine the genomic profile of 66 GISTs for which DNA of sufficient quality was available. No AURKA amplification was detected.
We therefore examined the CGH data for other alterations that could potentially explain the increased AURKA expression and poor clinical outcome. The CGH profiles ranged from simple, i.e. without any detectable changes, to complex, with multiple full chromosome and segmental gains and losses ( fig. 3a) . We compared the frequency of gains and losses for each probe between GISTs with and GISTs without metastatic
Research. December 13, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1610 outcome (Supplementary fig. 1 ). No significant difference in gains was observed, whereas several probes showed significant differences in losses. Among the top-ranked losses, the biggest difference was observed for eight probes on 9p21 deleted in 78.9% and 9.6% of the metastatic and non-metastatic cases, respectively (Supplementary fig.   1 ). All these probes target either the CDKN2A (3 probes), CDKN2B (3 probes) or MTAP (2 probes) loci. 9p21 deletions were observed in 18 patients (18/66 = 27%), of whom 13 developed metastases (13/18 = 72%). The deletions involved either the whole 9p arms or they were restricted to the CDKN2A/B loci (Supplementary fig. 2 ). They were scored as homozygous in 7 cases (6/7 with metastatic outcome) because of the very low CGH ratios (Supplementary fig. 2 ). These homozygous deletions allowed us to define more precisely the genes of interest since in two tumors the homozygous deletion excluded MTAP (GISTs #5 and #17). We checked the CDKN2A and CDKN2B copy number status by genomic qPCR and fully confirmed the exclusion of MTAP from the minimal deleted region. Interestingly, qPCR showed that the minimal deleted region included CDKN2A but not CDKN2B (GIST #5, table 2). As the Agilent gene expression probes target sequences common to the p14 and p16 mRNA, we performed RT-qPCR with primers specific for the individual transcripts (supplementary table 4). In all seven tumors lacking both copies of CDKN2A, and in three tumors with only one copy, both the p14 and p16 transcripts were absent or nearly absent. However, in two cases with CDKN2A deletion but without down-regulation of p14/p16 expression in the gene expression microrray data, we observed a specific decrease of p16 but not p14 expression, indicating that the target gene of the CDKN2A deletions is likely to be p16.
To explain metastatic cases without CDKN2A deletion, we sought other possible genomic alterations that could interfere with Restriction point control. We identified one homozygous deletion and 13 hemizygous deletions at the RB1 locus ( 
Do genomic changes predict GIST outcome?
The CGH profiles of the tumors that did not undergo metastasis had no or few losses or gains, generally involving whole chromosomes, whereas the tumors that developed metastases harbored more frequently segmental alterations. We therefore decided to test whether genome complexity could predict metastatic outcome ( fig. 3a ).
To take into account the number and the type of changes, a Genomic Index (GI) was calculated for each profile as follows: GI= A² / C, where A is the total number of alterations (segmental gains and losses) and C is the number of involved chromosomes. The Genomic Index across the entire series ranged from 0 to 56. The proportion of metastatic cases increased with Genomic Index. Metastatic cases predominated when the Genomic Index was over 10 (Table 2 and Research. 
Discussion
The development of a valid and reliable, investigator-independent method of GIST prognostication is essential for the proper clinical management of GIST patients, especially in the context of adjuvant treatment, where many patients are exposed to imatinib while only a small proportion will likely benefit from such treatment (21).
The main conclusion from this study is that the CINSARC score is a strong and validated predictor of metastasis in patients with GISTs. Remarkably, none of the patients assigned to the good prognosis group developed metastases or relapsed.
Prognostic expression signatures have demonstrated their experimental efficacy in several other tumor types but their clinical application has been complicated by technical issues such as weak reproducibility across array platforms. Importantly, we show here that CINSARC scoring is platform independent: the signature we developed on Affymetrix data was applied and validated here on Agilent data. Furthermore, the CINSARC score was prognostic for both the non-translocation related sarcomas on which it was originally developed (18) and for the GISTs in this study.
The CINSARC signature comprises 67 genes involved in maintenance of chromosome integrity and mitotic control, indicating that these processes play a crucial role in the development of metastasis in sarcomas (18). Supervised analysis showed that 45 of the 227 genes prognostic in GISTs were common to the CINSARC signature.
The top-ranked gene common to both approaches was AURKA. The AURKA protein is a mitotic centrosomal protein kinase amplified in many cancer types (22) (23) (24) (25) . Increased AURKA expression is associated with poor prognosis in breast carcinoma (26), colon carcinoma (27, 28), neuroblastoma (29) Author Manuscript Published OnlineFirst on December 13, 2011; DOI: 10.1158 /1078 -0432.CCR-11-1610 chromosome losses are the most frequently observed alterations in GISTs and are assumed to originate from unequal chromosome segregation, which can be induced by AURKA over-expression (31). Contrary to the mechanism seen in other cancers, AURKA over-expression in GISTs is not explained by gene amplification, but is instead a secondary change we postulate to be caused by defects in Restriction point control.
Our results point to AURKA being a very interesting potential therapeutic target in GISTs. With this in mind, it is noteworthy that immunohistochemistry shows that AURKA mRNA over-expression translates into AURKA protein over-expression (Supplementary fig. 3 ). AURKA inhibitors have entered clinical trials (32-36) and could be particularly useful for imatinib-resistant GISTs that have not yet disseminated since AURKA could be an essential event leading to acquisition of metastatic potential.
Previous copy number studies identified few aberrations in GISTs, deletions being more common than gains (6, 10-12, 37-39). The authors concluded that chromosome 14, 22 and 1p deletions were the most frequent aberrations. Two studies noted that copy number changes were commoner in high-risk GISTs but did not identify a clear cut-off delineating the high risk group (6, 10). At the expression level, most studies were designed to facilitate diagnosis (40, 41) or to predict KIT or PDGFRA mutation status (42-44). Yamaguchi and colleagues (17) performed gene expression profiling on 32 GISTs and identified CD26 as a prognostic marker, but only in GISTs of gastric origin. They concluded that CD26 might not be the cause of malignant progression of gastric GISTs. In contrast, our study demonstrates that CINSARC score, AURKA expression and Genomic Index are prognostic irrespective of the tumor location (Supplementary fig. 4 ). Furthermore, the biological meaning of CINSARC score and its association with genomic changes strongly indicate that CINSARC genes are implicated in malignant progression and are not just a consequence of the process. This
Research. DOI: 10.1158 /1078 -0432.CCR-11-1610 we show that CINSARC score, AURKA expression and Genomic Index all outperform the AFIP classification (table 3b and Table 2 Research. Table 3 Research. Table 2 : Results summary of the CINSARC analysis, AURKA expression (A: 9.15 as cut-off), CGH analysis (GI: 10 as cut-off) and CDKN2A/2B and RB1 copy number determined by genomic qPCR and array-CGH, respectively (2 = without detectable deletion; 1 = hemizygous deletion; 0 = no copy). The "pathway" column indicates the p16/RB1 pathway status: N= normal; 1= one copy of one gene is altered; 0= one gene is completely inactivated. Tumor are sorted according to CINSARC, AURKA expression and GI stratification P = PDGFRA, K = KIT, WT= Wild type, nd = not done. 
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